A Phase 2 Study of ARX788 in unresectable and/or metastatic breast cancer with low expression
A single arm, phase 2 study of ARX788 in unresectable and/or metastatic breast cancer with
low expression of HER2. Subjects should received ≥2 lines of systemic chemotherapy regimens
for recurrent or metastatic disease, and for HR positive subjects, also need to have received
≥2-line endocrine therapy ± targeted therapy (including neoadjuvant/adjuvant therapy). HER2
low expression is defined as HER2 IHC 1+ or HER2 IHC 2+ and FISH negative. The ARX788 will be
administered every 3 weeks (Q3W) intravenous (IV) infusion.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.